Century Therapeutics presents initial CNTY-101 data supporting multi-dosing strategy at ASH

Century Therapeutics, Inc.

Single-patient case study at Dose Level 1 (100 million cells) showed six-month durable complete response in high-risk R/R B-cell lymphoma
CNTY-101 was generally well tolerated with no dose-limiting toxicities, cytokine release syndrome, or neurotoxicity observed
Pharmacokinetic data suggested CNTY-101 exposure maintained upon additional cycles without lymphodepletion due to lack of allo-rejection
Company to host conference call Dec 11 to review additional clinical results from Dose Levels 1 and 2 and plans for systemic lupus erythematosus

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.